Shay Capital’s Sage Therapeutics SAGE Stock Holding History

Shay Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,000	Closed	-$252K	–	556
2023 Q1	$252K	Buy	+6,000	New	+$258K	0.05%	262

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Shay Capital's SAGE Position: Q2 2023 in Review

Shay Capital sold out of Sage Therapeutics (SAGE) in Q2 2023, closing a stake of 6,000 shares — an estimated $252K sold.

Shay Capital first reported a position in SAGE in Q1 2023 and held it in 1 quarter. The position peaked at $252K in Q1 2023. 224 funds tracked by Wall St. Rank hold SAGE as of Q2 2023.

Shay Capital reported no remaining Sage Therapeutics position as of Q2 2023 after selling out during the quarter.
Shay Capital sold 6,000 Sage Therapeutics shares in Q2 2023, an estimated $252K.
Shay Capital first reported a position in Sage Therapeutics in Q1 2023 and held it in 1 quarter.
Shay Capital's Sage Therapeutics position peaked at $252K in Q1 2023.
224 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2023.

Based on Shay Capital's 13F filing for Q2 2023, filed 14 Aug 2023.